| Literature DB >> 20541652 |
C N Patel1, A R Goldstone, F U Chowdhury, A F Scarsbrook.
Abstract
Integrated positron-emission tomography/computed tomography (PET/CT) with 2-[(18)F]-fluoro-2-deoxy-D-glucose (FDG) has revolutionized oncological imaging in recent years and now has a firmly established role in a variety of tumour types. There have been simultaneous step-wise advances in scanner technology, which are yet to be exploited to their full potential in clinical practice. This article will review these technological developments and explore how refinements in imaging protocols can further improve the accuracy and efficacy of PET/CT in oncology. The promises, and limitations, of emerging oncological applications of FDG PET/CT in radiotherapy planning and therapy response assessment will be explored. Potential future developments, including the use of FDG PET probes in oncological surgery, advanced data analysis techniques, and the prospect of integrated PET/magnetic resonance imaging (PET/MRI) will be highlighted. Copyright 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20541652 DOI： 10.1016/j.crad.2010.01.003
Source DB: PubMed Journal: Clin Radiol ISSN： 0009-9260 Impact factor: 2.350